Game Changers 2016: MicroMass

Game Changers 2016: MicroMass
Game Changers 2016: MicroMass

What will be the most game-changing catalyst in industry's quest to become more patient-oriented?

Pharma's quest to become more patient-oriented has traditionally focused on listening to and addressing patient needs in relation to specific products. However, a true catalyst will require a shift in focus that goes beyond a product-centric perspective. Pharma must come to the realization that a more comprehensive look at patient needs should take into account both behavioral and clinical factors. This is an essential starting point and by addressing these whole patient needs, from drug development to commercialization, the door is open for pharma to stay relevant, deliver meaningful innovation, and drive optimal health outcomes.


Address: 100 Regency Forest Drive, Cary, NC 27518

Phone: 919-851-3182

Year Founded: 1994   

Employees: 85

Sample Clients: Pfizer, Janssen, UCB, Teva, Novo Nordisk, Sanofi, Novartis Oncology, United Therapeutics, GlaxoSmithKline, ­AstraZeneca, ViiV.

New Business Contact: Jude Kelly, director of new business development, 919-256-2401;


In today's healthcare environment, pharma is constantly looking for ways to provide value, improve the patient experience on therapy, and generate better patient outcomes.

MicroMass has always maintained that optimal patient outcomes are the key to success in healthcare. With more than 20 years of expertise in human health behavior, our highly specialized approach applies evidence-based strategies from health psychology and behavioral science to change patient and provider behavior to drive real-world results for our clients.

MicroMass has created patient and provider behavior change programs in more than 30 therapeutic categories. Our expertise in health behavior extends beyond an insulated group of individuals with degrees in behavioral science. At MicroMass, developing behavior change programs is an integrated capability. Creative, strategy, and account teams are trained in behavior change strategies, and our proprietary methods ensure that behavioral science is optimally applied to meet the needs of clients. MicroMass has practical experience in developing and deployingbehavior-based programs for pharma, healthcare systems, and accountable care organizations. And our expertise is unrivaled in the industry.


Achieving optimal real-world outcomes requires more than persuasive messaging, education, and access to technology — it requires a specialized approach that impacts attitudes, builds skills, and changes behaviors.

MicroMass integrates behavioral science, creative, and technology to create real-world solutions in five areas:

• Patient engagement and support

• Relationship marketing

• Precommercial and clinical communications

• Provider advocacy and nonpersonal promotion

• Health behavior training and consulting

In addition, MicroMass is constantly looking to apply behavioral science in innovative ways to effectively solve challenges faced by our clients and the pharma industry. These initiatives include solutions for the patient, provider, and clinical field teams.

Our newest innovation is an integrated patient-­provider solution that goes beyond a clinical approach to address whole patient needs. It starts with an understanding of the clinical, behavioral, and psychosocial needs of patients using innovative tools, including Landmark Surveys, to generate real-world data.

Results that shed light on whole-patient needs are then leveraged to generate solutions that are delivered through clinical field teams. Field teams are trained in evidence-based approaches that address the psychosocial and clinical needs of patients. These teams also deliver tools and ongoing communications that optimize experience on therapy. This whole-patient approach supplements conventional awareness efforts with active motivation and skill-building programs to accelerate product awareness and adoption and ultimately drive toward optimal outcomes.


Next Article in Sponsored